A Study of Injection HB002.1T in Subjects With Solid Tumor

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with solid tumor.
Epistemonikos ID: 84e20fa1d76b170211b4d8b6d43c53a1f0a0dfbe
First added on: May 21, 2024